NVCR: NovoCure Limited
Performance
NVCR +14.74%
Watchlist
Select an item
Summary
NVCR at a glance
NVCR returned +14.74% over the past year and -34.73% a year over five years. Its worst drop in that year was -37.32%, smaller than 42% of stocks on Redstone, and its Sharpe ratio of 0.51 beats 51% of stocks on Redstone. It pays no dividends.
Current Drawdown
-37.32%
Rolling Volatility
65.38%
Actions
Metrics
Risk Indicators
Alpha27.01%
Beta1.45x
Sharpe0.51
Sortino0.87
Omega1.11
Calmar0.40
Martin2.41
Profile
About NVCR
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers.
- Sector
- Health Care
- Industry
- Surgical & Medical Instruments & Apparatus
- Market cap
- $1.5B
- Listed
- Oct 2015
- Employees
- 1,605
- Headquarters
- St. Helier
- Website
- novocure.com
Comparisons